Pfizer is looking to Asia for both R&D and manufacturing
outsourcing and to help it cut costs in a bid to mitigate the
effects of patent expiries and competition from generic drugs.
After a clinical hiccough five months ago set Coley
Pharmaceutical's drug development funding back several years,
Pfizer has stepped in to save the day, snapping up the biotech for
$164m.
Pfizer yesterday announced a multi-million dollar pay-off to
ex-partner Nektar Therapeutics, but the details of the deal reveal
not only Nektar's concerns for its future, but also that Pfizer is
still keeping its fingers in the...
Swedish construction firm Skanska today announced that it has been
awarded a multi-million dollar contract to expand a pharmaceutical
facility in the US, though the company is keeping the identity of
its client close to its chest.
As it faces an increasingly uncertain financial future, Pfizer's
reaffirmation that it plans to retain its focus on cutting costs,
including outsourcing and offshoring, comes as no 'Kindler
surprise', unlike the firm's...
As the fires in California continue to rage, Pfizer and other
pharma and biotech companies all over Southern California are
bracing themselves for closures and even evacuations of their
facilities.
We've all cringed at stories of people dumping their partners via
text message but in the world of business, Pfizer seems to have
taken things to a new level when its Exubera partners were
allegedly left to find out the product...
With yesterday's perhaps unsurprising news that Pfizer has cut its
losses and pulled out of the inhaled insulin market by dropping
Exubera and giving up on second generation devices, the world's
biggest pharma firm is in...
Pfizer revealed today that it is abandoning its once-touted
blockbuster Exubera, ending months of speculation as to whether the
fledging world-first inhalable insulin would sink or swim in the
fierce waters of pharma.
Rumours that Pfizer is looking into buying a large stake in
Sanofi-Aventis, which could be seen as a prelude to a full takeover
bid, has prompted a flurry of shareholder activity.
Pfizer has launched a new independent biotech centre and announced
five new senior appointments - not least a new head of R&D
- all geared towards reinvigorating the firm.
Pfizer will appear this week in a Nigerian court to face
allegations that it caused the death of Nigerian children over a
decade ago when it conducted a clinical trial of its
meningitis drug Trovan (trovafloxacin) in the country.
Following the recent news that pharma heavyweight Pfizer has also
been struck by contamination of its HIV drug Viracept (nelfinavir),
in-PharmaTechnologist.com spoke to the US Food and Drug
Administration (FDA) to find out how far...
Pfizer is considering offers from investors in a bid to spin off
its drug research and development laboratory in Japan and make it
an independent entity, according to media reports.
Yet another production site has fallen to the unrelenting axe of
big pharma's consolidation drive as Pfizer announces that its only
UK manufacturing plant is to be closed down.
It appears that pharma heavyweight Pfizer has not emerged unscathed
from the contamination chaos that has affected EU supplies of HIV
drug Viracept (nelfinavir), with the company this week warning that
its version of the treatment...
In a round up of the latest news in pharma research, Pfizer and
Bristol-Myers Squibb have big plans for DGAT-1 in obesity and
diabetes, GlaxoSmithKline is extra keen on Exelixis' anticancer
drug, Takeda is talking TLRs and UK...
Pfizer announced today it is breaking ground on a $50m expansion of
its biologics pilot plant in Chesterfield in a move that comes at
time when the drug giant is cutting back in other business
areas.
Pfizer was taken by surprise this week as a US engineering firm
announced that it had been awarded a contract to manage
construction of the firm's proposed biotech production plant in
Ireland, before the plant plans themselves...
Pfizer has penned a discovery-stage deal with Icagen aimed at
finding potential pain alleviating drugs, but has forked out over
twice the industry average.
Pfizer has had its first day in a Nigerian court in a legal dispute
over its alleged involvement in the death of Nigerian children
during a clinical trial 11 years ago.
In the latest episode of the Viracept contamination case, the drug
is now at risk of losing its marketing authorisation across Europe
while the dangers posed by the chemical contaminant are established
and manufacturer Roche rectifies...
Pfizer is facing fresh legal action from the Nigerian government
over its alleged involvement in the deaths of children it gave
an experimental drug to, more than a decade after the incident
occurred.
West Pharmaceutical Services reported a 40 per cent increase in
operating profit for the first quarter of 2007, despite profits
diving 43 per cent in the Tech Group business that makes the
delivery device for Pfizer's inhaled...
Bristol-Myers Squibb (BMS) has announced its second collaboration
this year with a fellow big pharma firm, aimed once again at
reducing the inherent risk of drug development.
After a troubling few months, Pfizer has announced some good news -
US regulators have recommended its first-in-class HIV/AIDS drug
should be approved.
Pfizer has shunned a more traditional approach to data management
outsourcing by slashing its vendors to a handful and standardising
them under the one business model.
While the market performance of Exubera may have fallen short of
expectations, Pfizer's inhaled insulin has opened the door for a
wider variety of macromolecules to take the pulmonary delivery
route.
Pfizer has homed in pSivida's controlled release drug delivery
technology, signing a research and licensing deal worth $165m
(€123.5m) and focusing keenly on the company's Medidur technology
for new ophthalmic applications.
Suggestions that Pfizer's scrapped cholesterol drug could actually
make coronary artery disease worse could set hearts racing among
others developing drugs in the same class.
French firm Valois Pharma will be providing Generex with a novel
valve for its pressurised metered dose inhaler (pMDI), used for its
innovative method of buccal delivery of insulin.
Heavyweight Pfizer is the latest pharmaceutical to cut
manufacturing capacity and shut down plants as it announces the
closure and sale of active pharmaceutical ingredient (API)
facilities in Ireland.
Roche is the latest large pharma company to restructure its
research and development into smaller disease-specific divisions to
help get drugs on the market faster.
Pfizer's latest cutbacks will provide a new outsourcing opportunity
for contract manufacturing organisations (CMOs) in low-cost
destinations as the drug giant announces plans to double its amount
of drug production outsourcing.
Pfizer has announced it will axe 10,000 jobs and close facilities
in a further effort to save on costs; the move comes in the face of
patent expiries for their biggest drugs and the failure of a
late-stage pipeline project.
In response to mounting media speculation of another major
restructuring drive, sparked off by an article in the Wall Street
Journal (WSJ), Pfizer has called a meeting to discuss its strategic
direction, with CEO Jeffrey B. Kindler...
Pfizer has entered a capacity expansion phase, to meet requirements
of global manufacturing of Genotropin (somatropin), a top-selling
human growth hormone.
A hefty investment by Pfizer in an Irish manufacturing facility
could prove to be a waste after the potential blockbuster it was
designed to make has been canned.
A liquidation sale will be held to offload unwanted manufacturing
equipment at a plant formerly owned by Pfizer - much of which is
new and was never turned on or certified.
Developing new drugs represents an enormous expense for pharma
companies with top firms spending up to £4bn (€6bn) a year on
R&D, according to new industry report.
Pfizer has revealed details of its new agreement with Transtech
Pharma in which the two companies will focus on the receptor for
advanced glycation end products (RAGE) with potential for use in
treating Alzheimer's disease.
Pfizer's manufacturing reforms have claimed more casualties in two
North American plants as the world's largest drugmaker battles to
realign production capacity with future product mix, new
technologies and cost effectiveness.
Successful technology transfer and effective management can help
avoid disappointment with contract manufacturing arrangements,
which often fail to live up to pharmaceutical company expectations.
TNS Healthcare has scooped up a new deal with Pfizer to provide the
drug giant's UK arm with sales and market information in order to
help them achieve their sales objectives.
Drug giant Pfizer is claiming victory in defending the world's most
prescribed branded medicine for treating hypertension after a US
court ruled that Dutch drugmaker Synthon's generic copy of Norvasc
(amlodipine besylate)...
Partnerships in drug delivery need to fairly reflect the risk all
parties take but there must also be a champion to drive the project
forward, according to Pfizer's director of drug delivery.
Although patent expirations are set to increase the size of the
generic drug market, the impact of greater scrutiny from healthcare
policymakers means that generic manufacturers may make more drugs
but not necessarily more money.